Biospring Holding Gmbh

What Biospring Holding Gmbh does

BioSpring Holding GmbH is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Frankfurt am Main, Germany, specializing in the GMP-compliant manufacturing and analysis of nucleic acid therapeutics. Founded in 1997, the company operates across two established sites in Frankfurt-Fechenheim (Sites I and II) comprising 22,700 m² with 10 cGMP cleanrooms, and is constructing a third multi-ton-scale facility in Offenbach (Site III, 15,800 m²) due for Q1 2028 completion. BioSpring has held cGMP certification continuously since 2007 and its facilities are FDA- and ANVISA-inspected.

The company's technical platform spans the major nucleic acid modalities relevant to modern drug development — antisense oligonucleotides (ASOs), small interfering RNA (siRNA), guide RNA (gRNA), messenger RNA (mRNA), CpG oligodeoxynucleotides (CpG ODNs), and increasingly differentiated offerings including Antibody-Oligonucleotide Conjugates (AOCs, commercial since 2020) and XNA-modified oligonucleotides integrated via a partnership with Luxna Biotech. Manufacturing is offered across five quality grades (Research, Preclinical, Pre-GMP, cGMP Clinical, cGMP Commercial, and Diagnostic), supported by in-house analytical and bioanalytical services including LC-MS/MS, hELISA, qPCR, method development/validation per ICH Q14 and Q2(R2), and release and stability testing. BioSpring currently supports APIs in 9 commercial programs and hundreds of clinical trials globally, including 4 approved mRNA products via its IVT platform.

BioSpring generates revenue through fee-for-service contract manufacturing and analytical engagements priced on a quote basis, reflecting the bespoke nature of each client's sequence, modality, grade, and scale requirements. Engagement is direct enterprise sales with dedicated project managers and technical experts assigned per program. The company is founder-led under CEO Dr. Sylvia Wojczewski and CSO Dr. Hüseyin Aygün, has not disclosed external funding, and appears to finance capacity expansion — most notably the several-hundred-million-euro Site III investment — through operational cash flow. Customer segments are pharmaceutical and biotechnology companies (primary) plus academic and research institutions, served across the US, UK, Germany, and additional global markets.

Name

Biospring Holding Gmbh

Legal name

BioSpring Gesellschaft für Biotechnologie mbH

Website

https://biospring.net

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

501–1,000 employees

Short description

BioSpring is a privately held German CDMO founded in 1997 that manufactures and analyzes nucleic acid therapeutics — including ASOs, siRNA, guide RNA, mRNA, and antibody-oligonucleotide conjugates — under cGMP for pharmaceutical, biotechnology, and academic clients from research through commercial supply.

Ownership category

akta.pro rank

Product category

Contract Development & Manufacturing (CDMO) Services for Nucleic Acid Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

akta.pro secondary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Contract manufacturing services
• Oligonucleotide CDMO
• MRNA manufacturing services
• Nucleic acid therapeutics
• Analytical testing services

Headquarters

HQ city

Frankfort

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Contract Manufacturing Services (CDMO): BioSpring generates revenue as a Contract Development and Manufacturing Organization (CDMO), providing fee-for-service manufacturing and analytical services to pharmaceutical and biotech clients across all stages of drug development — from research-grade and preclinical through clinical (cGMP Phase I-III) to commercial-scale production of nucleic acid APIs. Revenue is derived from custom manufacturing projects, analytical testing services, process development, and regulatory support, with pricing quote-based given the bespoke nature of client programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

BioSpring is a global GMP-certified Contract Development and Manufacturing Organization (CDMO) providing end-to-end manufacturing and analytical services for nucleic acid therapeutics. The company manufactures oligonucleotides (ASOs, siRNA, guide RNA, CpG ODNs, AOCs, XNA-modified) and mRNA under multiple quality grades from research through commercial cGMP supply, supported by bioanalytical testing, characterization, method development/validation, release/stability testing, and regulatory submission support (IND, IMPD, NDA, MAA, BLA, DMF).

Product overview

BioSpring is a global GMP-certified Contract Development and Manufacturing Organization (CDMO) specializing in nucleic acid therapeutics. The company operates a platform-plus-services architecture offering manufacturing across multiple nucleic acid modalities (mRNA, siRNA, ASOs, guide RNA, CpG ODNs, AOCs, and XNA-modified oligonucleotides) at all clinical phases from research to commercial scale, complemented by comprehensive analytical services including bioanalytical testing, characterization, method development/validation, and release/stability testing. The portfolio spans five manufacturing grades (cGMP Commercial/Clinical, Pre-GMP, Preclinical, Research, and Diagnostic) and integrated services covering project management, process development, and regulatory support for global submissions.

Differentiator

Problem solved

Functional benefit

Products and services

• GMP Oligonucleotide CDMO Services Comprehensive contract manufacturing and analytical services for oligonucleotides and mRNA, spanning preclinical development through commercial-scale production under cGMP conditions; designed for pharmaceutical and biotech therapeutic developers.
• Antisense Oligonucleotide (ASO) Manufacturing Manufacturing of short synthetic ASO strands designed to specifically bind RNA molecules and modulate gene expression through RNase H recruitment, for treating genetic disorders, cancer, and viral infections.
• mRNA (IVT) Manufacturing Custom IVT-mRNA manufacturing from research through cGMP scale, including capping, poly(A) tail modifications, and HPLC purification; supports batch sizes up to 250g for GMP production for clinical and commercial applications.
• siRNA Manufacturing Manufacturing of double-stranded siRNA molecules (20-25 base pairs) that induce RNA interference via the RISC complex for targeted gene silencing in antiviral and disease therapeutics.
• guide RNA (gRNA) Manufacturing Manufacturing of RNA molecules that guide CRISPR-Cas and base-editing tools to specific genomic locations for precise genetic modifications in cell and gene therapy applications.
• CpG Oligodeoxynucleotide (CpG ODN) Manufacturing Manufacturing of synthetic DNA sequences containing CpG motifs that stimulate immune responses via Toll-like receptor 9 (TLR9) for immunotherapy applications.
• Antibody-Oligonucleotide Conjugate (AOC) Manufacturing Bioconjugate manufacturing that chemically links oligonucleotide payloads (siRNA or ASOs) to antibody-based targeting elements for tissue-specific delivery, particularly extrahepatic applications including skeletal muscle and CNS; GMP manufacturing since 2016 and commercial manufacturing since 2020.
• XNA-Modified Oligonucleotide Manufacturing Manufacturing of xeno-nucleic acid (XNA)-modified oligonucleotides using AmNA, scpBNA, and 5-CP amidites (partnered with Luxna Biotech) for enhanced target binding, improved metabolic stability, and reduced toxicity in liver and brain.
• Other Nucleic Acid Modality Manufacturing (AntagomiRs, Aptamers, miRNAs, shRNAs, tRNAs) Manufacturing of additional nucleic acid modalities including chemically engineered antagomiRs for miRNA silencing, aptamers for targeted molecular binding, microRNAs, short hairpin RNAs, and transfer RNAs for specialized therapeutic applications.
• cGMP Commercial & Clinical Manufacturing ICH Q7-compliant cGMP-certified manufacturing for clinical Phase I-III and commercial production, supporting batch sizes from grams to multi-kilogram scale for high-demand commercial programs.
• Pre-GMP Manufacturing Manufacturing services for late-stage preclinical and early clinical phases prior to cGMP certification, supporting smooth transitions to full GMP production.
• Preclinical Manufacturing Early preclinical and mid-scale batch manufacturing for toxicology studies and preclinical animal trials, supporting scale-up to clinical production.
• Research-Grade Manufacturing Small-scale manufacturing from micrograms to multi-gram for lead screening, molecule optimization, and basic research applications.
• Diagnostic Manufacturing Manufacturing services for diagnostic-grade nucleic acids meeting quality requirements for in vitro diagnostic applications.
• Bioanalytical Services Comprehensive bioanalytical testing including extraction from biofluids/tissues, quantification by hELISA, LC, LC-MS, LC-MS/MS, and qPCR in the lower ng/mL range, metabolic stability assessment, pharmacokinetics, and metabolite identification.
• Analytical Characterization Services Physicochemical characterization of oligonucleotides including DSC for thermal analysis, spectroscopic methods (UV-Vis, fluorescence, CD), and DLS for size and aggregation assessment.
• Method Development & Transfer Analytical method development and transfer services aligned with ICH Q14 guidelines, supporting stage-appropriate validation from early development through commercialization.
• Method Validation Comprehensive method validation following ICH Q14 and ICH Q2(R2) guidelines with rigorous assessment of accuracy, precision, specificity, and robustness for regulatory filings.
• Release & Stability Testing FDA-inspected, cGMP-certified release testing and ICH-compliant stability studies supporting eight commercial oligonucleotide products.
• Additional Analytical Services Specialized analytical services including dose-formulation analysis, characterization in complex formulations (LNPs, polymeric carriers), physicochemical characterization in solution, and in vitro bioactivity assays.
• Integrated Services (Project Management, Process Development, Regulatory Support) End-to-end project management, process development, and regulatory filing support including documentation for IND, IMPD, NDA, MAA, J-NDA, BLA, and DMF submissions.

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Luxna Biotech Co., Ltd.coreTechnology or IntegrationLuxna Biotech Co., Ltd. is a technology partner for XNA (xeno-nucleic acid) amidites including AmNA, scpBNA, and 5-CP. These XNAs were originally developed through groundbreaking research at Osaka University and are marketed by Luxna Biotech. BioSpring integrates these proprietary amidites into its manufacturing services for XNA-modified oligonucleotides, enabling clients to access next-generation nucleic acid modifications that offer enhanced target binding, improved metabolic stability, and reduced toxicity in liver and brain.

Scale indicators9 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Nitto Denko Avecia: One of the largest dedicated oligonucleotide CDMOs globally, providing GMP-scale manufacturing of ASOs, siRNA and other nucleic acid APIs. Directly comparable to BioSpring on modality mix, customer base (pharma/biotech sponsors) and service scope (manufacturing + analytical).
• Eurofins Genomics: Manufactures oligonucleotides and provides nucleic acid analytical services from research through GMP scale. Comparable to BioSpring on oligo manufacturing and analytical service delivery, with broader genomics adjacencies.
• TriLink BioTechnologies (Maravai LifeSciences): Specialist CDMO for mRNA and oligonucleotide GMP manufacturing with proprietary CleanCap capping technology. Highly comparable to BioSpring's IVT mRNA platform and oligonucleotide service offering, serving the same biotech/pharma sponsors for clinical and commercial supply.
• CordenPharma: European-headquartered CDMO with dedicated oligonucleotide and peptide API manufacturing capabilities. Closely comparable to BioSpring on modality focus, geographic base, and end-to-end GMP manufacturing-plus-analytical service model.
• Aldevron (Danaher): Specialist CDMO for plasmid DNA, mRNA and proteins serving gene therapy and nucleic acid therapeutic developers. Comparable to BioSpring on nucleic acid API manufacturing for clinical and commercial programs across a global pharma/biotech customer base.
• Asahi Kasei Bioprocess (Axolabs): Operates Axolabs, a dedicated oligonucleotide CDMO with strong ASO/siRNA/GalNAc-conjugate manufacturing capabilities. Direct peer to BioSpring on modality coverage, conjugation chemistry expertise, and GMP nucleic acid API supply for pharma/biotech.

Broad incumbents

• Lonza: Global top-tier CDMO expanding aggressively into oligonucleotide and mRNA manufacturing. Competes with BioSpring on commercial nucleic acid API supply but operates as a broad-portfolio incumbent across biologics, small molecules and cell therapies.
• Catalent (Novo Holdings): Major global CDMO with nucleic acid, cell therapy and biologics manufacturing capabilities. Overlaps with BioSpring on nucleic acid CDMO services but serves a much broader portfolio of sponsors and therapeutic categories.
• WuXi STA: CDMO arm of WuXi AppTec, offering oligonucleotide and nucleic acid manufacturing alongside broader small molecule and biologics services. Directly comparable service offering to BioSpring, but at greater scale and broader therapeutic coverage.
• Samsung Biologics: Large Asian CDMO building nucleic acid and mRNA manufacturing capacity to complement its biologics franchise. Overlaps with BioSpring on nucleic acid therapeutic manufacturing but at a much larger scale and broader modality set.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biospring-gmbh
• Instagraminstagram.com/biospring_de
• Facebookfacebook.com/BioSpringGmbH

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biospring Holding Gmbh